Axitinib Accord

Axitinib Accord is used to treat adults with advanced renal cell carcinoma, a type of kidney cancer. ‘Advanced’ means that the cancer has started to spread. Axitinib Accord is used when treatment with a medicine containing sunitinib or with ‘cytokines’ (other cancer medicines) has failed. Axitinib Accord contains the active substance axitinib and is a ‘generic medicine’. This means that Axitinib Accord contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU. The reference medicine for Axitinib Accord is Inlyta. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/other/questions-and-answers-generic-medicines_en.pdf).